Pacritinib — drug · CancerIndex

Regulatory

Approvals (1)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

openfdaRegulatory1 approval record · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
US FDA	—	VONJO is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a platelet count below 50 × 10 9 /L. This indication is approved under accelerated approval based on spleen volume reduction [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). VONJO is a kinase inhibitor indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10 9 /L ( 1 ). This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).accelerated	approved	Feb 28, 2022	openfda

Data updated 2 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 3	16	12	2	36	1	US	Feb 28, 2022	2008-07
Leukemia	Phase2	Phase 2	4	4	0	13	0	—	—	2008-08
Non-Hodgkin Lymphoma	Phase2	Phase 2	2	2	0	5	0	—	—	2010-12
Malignant Breast Neoplasm	Phase2	Phase 2	1	0	0	1	0	—	—

Curated evidence

Clinical evidence (6)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–6 of 6 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FLT3 ITD1
PacritinibCombination

Clinical trials

Trials with this intervention (36)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–36 of 36 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06303193	Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms	recruiting	Phase 1 / Phase 2	160	National Cancer Institute (NCI)NIH	1	Sep 28, 2026	clinicaltrials
NCT04282187	Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

EGFR G598V4
Afatinib + PacritinibCombination	GlioblastomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	submitted	EID8235 Patient-derived GBM brain tumour stem cells (BTSCs) were used to test the efficacy of the EGFR inhibitor afatinib and JAK2 inhibitor pacritinib in vitro. Combination treatment with afatinib and pacrit… (full text at CIViC) PMID 32226941 · Jensen et al., 2020 · Open in CIViC	civic
Erlotinib + PacritinibCombination	GlioblastomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	submitted	EID8236 Patient-derived GBM brain tumour stem cells (BTSCs) were used to test the efficacy of the EGFR inhibitor erlotinib and JAK2 inhibitor pacritinib in vitro. Combination treatment with erlotinib and pacr… (full text at CIViC) PMID 32226941 · Jensen et al., 2020 · Open in CIViC	civic
Lapatinib + PacritinibCombination	GlioblastomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	submitted	EID8261 Patient-derived GBM brain tumour stem cells (BTSCs) were used to test the efficacy of the EGFR inhibitor lapatinib and JAK2 inhibitor pacritinib in vitro. Combination treatment with lapatinib and pacr… (full text at CIViC) PMID 32226941 · Jensen et al., 2020 · Open in CIViC	civic
Osimertinib + PacritinibCombination	GlioblastomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	submitted	EID8284 Patient-derived GBM brain tumour stem cells (BTSCs) were used to test the efficacy of the EGFR inhibitor AZD9291 and JAK2 inhibitor pacritinib in vitro. Combination treatment with AZD9291 and pacritin… (full text at CIViC) PMID 32226941 · Jensen et al., 2020 · Open in CIViC	civic